SCHEMBL856186

SCHEMBL856186

CCCCOC(=O)N1C[CH]CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.55
LMNA P02545 2/20 0.55
POLB P06746 1/20 0.55
HRH2 P25021 5/20 0.41
HRH1 P35367 5/20 0.41
ALDH1A1 P00352 5/20 0.41
BCHE P06276 1/20 0.39
ATM Q13315 1/20 0.39
HPGD P15428 3/20 0.38
KMT2A Q03164 2/20 0.38
NAAA Q02083 1/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.37
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11120122 0.95 LMNA (0.50) SMN1; SMN2LMNAPOLBHRH2HRH1
SCHEMBL9989166 0.90 SMN1; SMN2 (0.53) SMN1; SMN2LMNAPOLBHRH2HRH1
SCHEMBL1713612 0.90 SMN1; SMN2 (0.42) SMN1; SMN2LMNAPOLBALDH1A1HPGD
SCHEMBL574934 0.90 SMN1; SMN2 (0.63) SMN1; SMN2LMNAPOLBHRH2HRH1
SCHEMBL1515381 0.86 LMNA (0.57) SMN1; SMN2LMNAPOLBHRH2HRH1
SCHEMBL5711411 0.85 SMN1; SMN2 (0.54) SMN1; SMN2LMNAPOLBHRH2HRH1
SCHEMBL30032180 0.85 SMN1; SMN2 (0.54) SMN1; SMN2LMNAPOLBHRH2HRH1
SCHEMBL1712987 0.84 TSHR (0.48) SMN1; SMN2LMNAPOLBALDH1A1ATM
SCHEMBL3950479 0.80 SMN1; SMN2 (0.41) SMN1; SMN2LMNAPOLBALDH1A1ATM
SCHEMBL9405372 0.80 POLB (0.73) SMN1; SMN2LMNAPOLBHRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3676297-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-07-08 EP claimed
WO-2019046779-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2019-03-07 WO claimed
EP-2350017-A1 AMIDE COMPOUNDS USEFUL IN THERAPY Pfizer Limited (GB) 2011-08-03 EP claimed
WO-2010032200-A1 AMIDE COMPOUNDS USEFUL IN THERAPY PFIZER LIMITED (GB) 2010-03-25 WO claimed
WO-2006067445-A2 CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-06-29 WO claimed
EP-2432760-A1 BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-03-28 EP disclosed
WO-2010134014-A1 BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-11-25 WO disclosed
WO-2009071691-A2 OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION ABBOTT GMBH & CO. KG (DE) 2009-06-11 WO disclosed
WO-2006067445-A2 CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed
CN-1049434-C Aromatic amidine derivatives and pharmaceutically acceptable salts thereof DAIICHI SEIYAKU CO (JP) 2000-02-16 CN disclosed
CN-1072677-A Aromatic amidine derivative and salt thereof DAIICHI SEIYAKU CO (JP) 1993-06-02 CN disclosed